Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease

TLDR

MPTP induces nigrostriatal dopaminergic neuron loss mimicking Parkinson’s disease, and prior work showed that iNOS ablation mitigates this neurotoxicity. The study aims to determine whether minocycline can protect nigrostriatal dopaminergic neurons by inhibiting microglial activation in the MPTP model of Parkinson’s disease. Minocycline, a tetracycline derivative that suppresses microglial activation independently of antimicrobial effects, reduces neuron loss and nitrotyrosine formation induced by MPTP. Minocycline blocks MPTP‑induced microglial activation, suppresses IL‑1β, NADPH‑oxidase, and iNOS activity, and confers additional neuroprotection even in iNOS‑deficient mice, underscoring the role of microglial inflammation in MPTP toxicity.

Abstract

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) damages the nigrostriatal dopaminergic pathway as seen in Parkinson's disease (PD), a common neurodegenerative disorder with no effective protective treatment. Consistent with a role of glial cells in PD neurodegeneration, here we show that minocycline, an approved tetracycline derivative that inhibits microglial activation independently of its antimicrobial properties, mitigates both the demise of nigrostriatal dopaminergic neurons and the formation of nitrotyrosine produced by MPTP. In addition, we show that minocycline not only prevents MPTP-induced activation of microglia but also the formation of mature interleukin-1beta and the activation of NADPH-oxidase and inducible nitric oxide synthase (iNOS), three key microglial-derived cytotoxic mediators. Previously, we demonstrated that ablation of iNOS attenuates MPTP-induced neurotoxicity. Now, we demonstrate that iNOS is not the only microglial-related culprit implicated in MPTP-induced toxicity because mutant iNOS-deficient mice treated with minocycline are more resistant to this neurotoxin than iNOS-deficient mice not treated with minocycline. This study demonstrates that microglial-related inflammatory events play a significant role in the MPTP neurotoxic process and suggests that minocycline may be a valuable neuroprotective agent for the treatment of PD.